For our patient, we started an initial regimen of β-blocker therapy for LQTS, but withheld implantable cardioverter-defibrillator placement unless he failed optimal medical management.8 It was only after 8 years of follow-up that he presented with worsening neurologic manifestations, at which point genetic studies for epilepsy revealed the TANGO2 variant. This evidence concerns the gene TANGO2 and epilepsy.